Dasatinib N-oxide-d₈ 

Dasatinib N-oxide-d₈ is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor[1][2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

512.05

C₂₂H₁₈D₈ClN₇O₃S

1189988-36-0

910297-52-8

OCC[N+]1([O-])C([2H])([2H])C([2H])([2H])N(C2=NC(C)=NC(NC3=NC=C(C(NC4=C(C)C=CC=C4Cl)=O)S3)=C2)C([2H])([2H])C1([2H])[2H]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]

  [2]. Christopher LJ, et, al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64.  [Content Brief]

  [3]. Furlong MT, et, al. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2012  [Content Brief]